<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37375809</PMID><DateRevised><Year>2023</Year><Month>07</Month><Day>01</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">1424-8247</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><Issue>6</Issue><PubDate><Year>2023</Year><Month>Jun</Month><Day>09</Day></PubDate></JournalIssue><Title>Pharmaceuticals (Basel, Switzerland)</Title><ISOAbbreviation>Pharmaceuticals (Basel)</ISOAbbreviation></Journal><ArticleTitle>Targeting Spike Glycoprotein S1 Mediated by NLRP3 Inflammasome Machinery and the Cytokine Releases in A549 Lung Epithelial Cells by Nanocurcumin.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">862</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ph16060862</ELocationID><Abstract><AbstractText>Chronic inflammation and tissue damage can result from uncontrolled inflammation during SARS-CoV-2 or COVID-19 infections, leading to post-acute COVID conditions or long COVID. Curcumin, found in turmeric, has potent anti-inflammatory properties but limited effectiveness. This study developed nanocurcumin, a curcumin nanoparticle, to enhance its physical and chemical stability and investigate its in vitro anti-inflammatory properties upon CoV2-SP induction in lung epithelial cells. Nanocurcumin was prepared by encapsulating curcumin extract in phospholipids. The particle size, polydispersity index, and zeta potential of nanocurcumin were measured using dynamic light scattering. The encapsulated curcumin content was determined using HPLC analysis. The encapsulation efficiency of curcumin was 90.74 &#xb1; 5.35% as determined by HPLC. Regarding the in vitro release of curcumin, nanocurcumin displayed a higher release content than non-nanoparticle curcumin. Nanocurcumin was further investigated for its anti-inflammatory properties using A549 lung epithelial cell line. As determined by ELISA, nanocurcumin showed inhibitory effects on inflammatory cytokine releases in CoV2-SP-stimulated conditions, as evidenced by a significant decrease in IL-6, IL-1&#x3b2; and IL-18 cytokine secretions compared with the spike-stimulated control group (<i>p</i> &lt; 0.05). Additionally, as determined by RT-PCR, nanocurcumin significantly inhibited the CoV2-SP-stimulated expression of inflammatory genes (<i>IL-6</i>, <i>IL-1&#x3b2;</i>, <i>IL-18</i>, and <i>NLRP3</i>) compared with the spike-stimulated control group (<i>p</i> &lt; 0.05). Regarding the inhibition of NLRP3 inflammasome machinery proteins by Western blot, nanocurcumin decreased the expressions of inflammasome machinery proteins including NLRP3, ASC, pro-caspase-1, and the active form of caspase-1 in CoV2-SP-stimulated A549 cells compared with the spike-stimulated control group (<i>p</i> &lt; 0.05). Overall, the nanoparticle formulation of curcumin improved its solubility and bioavailability, demonstrating anti-inflammatory effects in a CoV2-SP-induced scenario by inhibiting inflammatory mediators and the NLRP3 inflammasome machinery. Nanocurcumin shows promise as an anti-inflammatory product for preventing COVID-19-related airway inflammation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chittasupho</LastName><ForeName>Chuda</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-0696-9969</Identifier><AffiliationInfo><Affiliation>Department of Pharmaceutical Sciences, Faculty of Pharmacy, Chiang Mai University, Chiang Mai 50200, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Srisawad</LastName><ForeName>Kamonwan</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-0260-7215</Identifier><AffiliationInfo><Affiliation>Department of Biochemistry, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Anticarcinogenesis and Apoptosis Research Cluster, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arjsri</LastName><ForeName>Punnida</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-6249-4497</Identifier><AffiliationInfo><Affiliation>Department of Biochemistry, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Research and Development of Natural Products for Health, Chiang Mai University, Chiang Mai 50200, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Phongpradist</LastName><ForeName>Rungsinee</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Sciences, Faculty of Pharmacy, Chiang Mai University, Chiang Mai 50200, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tingya</LastName><ForeName>Wipawan</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Sciences, Faculty of Pharmacy, Chiang Mai University, Chiang Mai 50200, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ampasavate</LastName><ForeName>Chadarat</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-1464-0685</Identifier><AffiliationInfo><Affiliation>Department of Pharmaceutical Sciences, Faculty of Pharmacy, Chiang Mai University, Chiang Mai 50200, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dejkriengkraikul</LastName><ForeName>Pornngarm</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-8732-8911</Identifier><AffiliationInfo><Affiliation>Department of Biochemistry, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Anticarcinogenesis and Apoptosis Research Cluster, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Research and Development of Natural Products for Health, Chiang Mai University, Chiang Mai 50200, Thailand.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>FRB660046/0162_FF66/020</GrantID><Agency>Fundamental Fund, Chiang Mai University and Thailand Science Research and Innovation, Thailand</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Pharmaceuticals (Basel)</MedlineTA><NlmUniqueID>101238453</NlmUniqueID><ISSNLinking>1424-8247</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">A549 lung epithelial cells</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">inflammation</Keyword><Keyword MajorTopicYN="N">nanocurcumin</Keyword></KeywordList><CoiStatement>The authors declare they have no conflict of interest. The funders had no role in the design of the study; in the collection, analyses or interpretation of data; in the writing of the manuscript or in the decision to publish the results.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>4</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>6</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>6</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>28</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>28</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>28</Day><Hour>1</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>6</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37375809</ArticleId><ArticleId IdType="pmc">PMC10302714</ArticleId><ArticleId IdType="doi">10.3390/ph16060862</ArticleId><ArticleId IdType="pii">ph16060862</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Proal A.D., VanElzakker M.B. Long COVID or post-acute sequelae of COVID-19 (PASC): An overview of biological factors that may contribute to persistent symptoms. Front. Microbiol. 2021;12:1494. doi: 10.3389/fmicb.2021.698169.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2021.698169</ArticleId><ArticleId IdType="pmc">PMC8260991</ArticleId><ArticleId IdType="pubmed">34248921</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis H.E., McCorkell L., Vogel J.M., Topol E.J. Long COVID: Major findings, mechanisms and recommendations. Nat. Rev. Microbiol. 2023;21:133&#x2013;146. doi: 10.1038/s41579-022-00846-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Bormann M., Alt M., Schipper L., van de Sand L., Le-Trilling V.T.K., Rink L., Heinen N., Madel R.J., Otte M., Wuensch K. Turmeric root and its bioactive ingredient curcumin effectively neutralize SARS-CoV-2 in vitro. Viruses. 2021;13:1914. doi: 10.3390/v13101914.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13101914</ArticleId><ArticleId IdType="pmc">PMC8537626</ArticleId><ArticleId IdType="pubmed">34696344</ArticleId></ArticleIdList></Reference><Reference><Citation>Rattis B.A., Ramos S.G., Celes M. Curcumin as a Potential Treatment for COVID-19. Front. Pharmacol. 2021;12:1068. doi: 10.3389/fphar.2021.675287.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2021.675287</ArticleId><ArticleId IdType="pmc">PMC8138567</ArticleId><ArticleId IdType="pubmed">34025433</ArticleId></ArticleIdList></Reference><Reference><Citation>Vahedian-Azimi A., Abbasifard M., Rahimi-Bashar F., Guest P.C., Majeed M., Mohammadi A., Banach M., Jamialahmadi T., Sahebkar A. Effectiveness of curcumin on outcomes of hospitalized COVID-19 patients: A systematic review of clinical trials. Nutrients. 2022;14:256. doi: 10.3390/nu14020256.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu14020256</ArticleId><ArticleId IdType="pmc">PMC8779570</ArticleId><ArticleId IdType="pubmed">35057437</ArticleId></ArticleIdList></Reference><Reference><Citation>Tahmasebi S., El-Esawi M.A., Mahmoud Z.H., Timoshin A., Valizadeh H., Roshangar L., Varshoch M., Vaez A., Aslani S., Navashenaq J.G. Immunomodulatory effects of nanocurcumin on Th17 cell responses in mild and severe COVID-19 patients. J. Cell. Physiol. 2021;236:5325&#x2013;5338. doi: 10.1002/jcp.30233.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcp.30233</ArticleId><ArticleId IdType="pubmed">33372280</ArticleId></ArticleIdList></Reference><Reference><Citation>Pawar K.S., Mastud R.N., Pawar S.K., Pawar S.S., Bhoite R.R., Bhoite R.R., Kulkarni M.V., Deshpande A.R. Oral curcumin with piperine as adjuvant therapy for the treatment of COVID-19: A randomized clinical trial. Front. Pharmacol. 2021;12:1056. doi: 10.3389/fphar.2021.669362.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2021.669362</ArticleId><ArticleId IdType="pmc">PMC8193734</ArticleId><ArticleId IdType="pubmed">34122090</ArticleId></ArticleIdList></Reference><Reference><Citation>Dourado D., Freire D.T., Pereira D.T., Amaral-Machado L., Alencar &#xc9;.N., de Barros A.L.B., Egito E.S.T. Will curcumin nanosystems be the next promising antiviral alternatives in COVID-19 treatment trials? Biomed. Pharmacother. 2021;139:111578. doi: 10.1016/j.biopha.2021.111578.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2021.111578</ArticleId><ArticleId IdType="pmc">PMC8023207</ArticleId><ArticleId IdType="pubmed">33848774</ArticleId></ArticleIdList></Reference><Reference><Citation>Saber-Moghaddam N., Salari S., Hejazi S., Amini M., Taherzadeh Z., Eslami S., Rezayat S.M., Jaafari M.R., Elyasi S. Oral nano-curcumin formulation efficacy in management of mild to moderate hospitalized coronavirus disease-19 patients: An open label nonrandomized clinical trial. Phytother. Res. 2021;35:2616&#x2013;2623. doi: 10.1002/ptr.7004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ptr.7004</ArticleId><ArticleId IdType="pubmed">33389761</ArticleId></ArticleIdList></Reference><Reference><Citation>Valizadeh H., Abdolmohammadi-Vahid S., Danshina S., Gencer M.Z., Ammari A., Sadeghi A., Roshangar L., Aslani S., Esmaeilzadeh A., Ghaebi M. Nano-curcumin therapy, a promising method in modulating inflammatory cytokines in COVID-19 patients. Int. Immunopharmacol. 2020;89:107088. doi: 10.1016/j.intimp.2020.107088.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2020.107088</ArticleId><ArticleId IdType="pmc">PMC7574843</ArticleId><ArticleId IdType="pubmed">33129099</ArticleId></ArticleIdList></Reference><Reference><Citation>Dei Cas M., Ghidoni R. Dietary curcumin: Correlation between bioavailability and health potential. Nutrients. 2019;11:2147. doi: 10.3390/nu11092147.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu11092147</ArticleId><ArticleId IdType="pmc">PMC6770259</ArticleId><ArticleId IdType="pubmed">31500361</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma V.K., Prateeksha, Singh S.P., Singh B.N., Rao C.V., Barik S.K. Nanocurcumin Potently Inhibits SARS-CoV-2 Spike Protein-Induced Cytokine Storm by Deactivation of MAPK/NF-&#x3ba;B Signaling in Epithelial Cells. ACS Appl. Bio Mater. 2022;5:483&#x2013;491. doi: 10.1021/acsabm.1c00874.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsabm.1c00874</ArticleId><ArticleId IdType="pubmed">35112841</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamming I., Timens W., Bulthuis M., Lely A., Navis G.v., van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J. Pathol. J. Pathol. Soc. Great Br. Irel. 2004;203:631&#x2013;637. doi: 10.1002/path.1570.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/path.1570</ArticleId><ArticleId IdType="pmc">PMC7167720</ArticleId><ArticleId IdType="pubmed">15141377</ArticleId></ArticleIdList></Reference><Reference><Citation>Harcourt J., Tamin A., Lu X., Kamili S., Sakthivel S.K., Murray J., Queen K., Tao Y., Paden C.R., Zhang J. Severe acute respiratory syndrome coronavirus 2 from patient with coronavirus disease, United States. Emerg. Infect. Dis. 2020;26:1266&#x2013;1273. doi: 10.3201/eid2606.200516.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2606.200516</ArticleId><ArticleId IdType="pmc">PMC7258473</ArticleId><ArticleId IdType="pubmed">32160149</ArticleId></ArticleIdList></Reference><Reference><Citation>Gamage A.M., Tan K.S., Chan W.O., Liu J., Tan C.W., Ong Y.K., Thong M., Andiappan A.K., Anderson D.E., Wang D.Y. Infection of human Nasal Epithelial Cells with SARS-CoV-2 and a 382-nt deletion isolate lacking ORF8 reveals similar viral kinetics and host transcriptional profiles. PLoS Pathog. 2020;16:e1009130. doi: 10.1371/journal.ppat.1009130.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1009130</ArticleId><ArticleId IdType="pmc">PMC7746279</ArticleId><ArticleId IdType="pubmed">33284849</ArticleId></ArticleIdList></Reference><Reference><Citation>Lukassen S., Chua R.L., Trefzer T., Kahn N.C., Schneider M.A., Muley T., Winter H., Meister M., Veith C., Boots A.W. SARS-CoV-2 receptor ACE 2 and TMPRSS 2 are primarily expressed in bronchial transient secretory cells. EMBO J. 2020;39:e105114. doi: 10.15252/embj.20105114.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.20105114</ArticleId><ArticleId IdType="pmc">PMC7232010</ArticleId><ArticleId IdType="pubmed">32246845</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann M., Kleine-Weber H., Schroeder S., Kr&#xfc;ger N., Herrler T., Erichsen S., Schiergens T.S., Herrler G., Wu N.-H., Nitsche A. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271&#x2013;280.e8. doi: 10.1016/j.cell.2020.02.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.02.052</ArticleId><ArticleId IdType="pmc">PMC7102627</ArticleId><ArticleId IdType="pubmed">32142651</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryu G., Shin H.-W. SARS-CoV-2 infection of airway epithelial cells. Immune Netw. 2021;21:e3. doi: 10.4110/in.2021.21.e3.</Citation><ArticleIdList><ArticleId IdType="doi">10.4110/in.2021.21.e3</ArticleId><ArticleId IdType="pmc">PMC7937510</ArticleId><ArticleId IdType="pubmed">33728096</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan R., Zhang Y., Li Y., Xia L., Guo Y., Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 2020;367:1444&#x2013;1448. doi: 10.1126/science.abb2762.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abb2762</ArticleId><ArticleId IdType="pmc">PMC7164635</ArticleId><ArticleId IdType="pubmed">32132184</ArticleId></ArticleIdList></Reference><Reference><Citation>Cahaya S.T.H.D. Stability of curcumin in turmeric oleoresin-&#x3b2;-cyclodextrin inclusion complex during storage. Malays. J. Anal. Sci. 2009;13:1&#x2013;5.</Citation></Reference><Reference><Citation>Gholami L., Momtazi-Borojeni A.A., Malaekeh-Nikouei B., Nikfar B., Amanolahi F., Mohammadi A., Oskuee R.K. Selective Cellular Uptake and Cytotoxicity of Curcumin-encapsulated SPC and HSPC Liposome Nanoparticles on Human Bladder Cancer Cells. Curr. Pharm. Des. 2023;29:1046&#x2013;1058.</Citation><ArticleIdList><ArticleId IdType="pubmed">36999712</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiangnoon R., Samee W., Uttayarat P., Jittachai W., Ruksiriwanich W., Sommano S.R., Athikomkulchai S., Chittasupho C. Phytochemical Analysis, Antioxidant, and Wound Healing Activity of Pluchea indica L.(Less) Branch Extract Nanoparticles. Molecules. 2022;27:635. doi: 10.3390/molecules27030635.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules27030635</ArticleId><ArticleId IdType="pmc">PMC8839647</ArticleId><ArticleId IdType="pubmed">35163900</ArticleId></ArticleIdList></Reference><Reference><Citation>Datta S., Jutkov&#xe1; A., &#x160;r&#xe1;mkov&#xe1; P., Lenkavsk&#xe1; L., Hunto&#x161;ov&#xe1; V., Chorv&#xe1;t D., Mi&#x161;kovsk&#xfd; P., Jancura D., Kronek J. Unravelling the excellent chemical stability and bioavailability of solvent responsive curcumin-loaded 2-ethyl-2-oxazoline-grad-2-(4-dodecyloxyphenyl)-2-oxazoline copolymer nanoparticles for drug delivery. Biomacromolecules. 2018;19:2459&#x2013;2471. doi: 10.1021/acs.biomac.8b00057.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.biomac.8b00057</ArticleId><ArticleId IdType="pubmed">29634248</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodrigues T.S., de S&#xe1; K.S., Ishimoto A.Y., Becerra A., Oliveira S., Almeida L., Gon&#xe7;alves A.V., Perucello D.B., Andrade W.A., Castro R. Inflammasomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients. J. Exp. Med. 2021;218:e20201707. doi: 10.1084/jem.20201707.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20201707</ArticleId><ArticleId IdType="pmc">PMC7684031</ArticleId><ArticleId IdType="pubmed">33231615</ArticleId></ArticleIdList></Reference><Reference><Citation>Dos Santos Bezerra R., Valen&#xe7;a I.N., de Cassia Ruy P., Ximenez J.P., da Silva Junior W.A., Covas D.T., Kashima S., Slavov S.N. The novel coronavirus SARS-CoV-2: From a zoonotic infection to coronavirus disease 2019. J. Med. Virol. 2020;92:2607&#x2013;2615. doi: 10.1002/jmv.26072.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26072</ArticleId><ArticleId IdType="pmc">PMC7283665</ArticleId><ArticleId IdType="pubmed">32470173</ArticleId></ArticleIdList></Reference><Reference><Citation>Desforges M., Le Coupanec A., Dubeau P., Bourgouin A., Lajoie L., Dub&#xe9; M., Talbot P.J. Human coronaviruses and other respiratory viruses: Underestimated opportunistic pathogens of the central nervous system? Viruses. 2019;12:14. doi: 10.3390/v12010014.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v12010014</ArticleId><ArticleId IdType="pmc">PMC7020001</ArticleId><ArticleId IdType="pubmed">31861926</ArticleId></ArticleIdList></Reference><Reference><Citation>Churilov L.P., Normatov M.G., Utekhin V.J. Molecular Mimicry between SARS-CoV-2 and Human Endocrinocytes: A Prerequisite of Post-COVID-19 Endocrine Autoimmunity? Pathophysiology. 2022;29:486&#x2013;494. doi: 10.3390/pathophysiology29030039.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathophysiology29030039</ArticleId><ArticleId IdType="pmc">PMC9504401</ArticleId><ArticleId IdType="pubmed">36136066</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y., Liu Q., Guo D. Emerging coronaviruses: Genome structure, replication, and pathogenesis. J. Med. Virol. 2020;92:418&#x2013;423. doi: 10.1002/jmv.25681.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.25681</ArticleId><ArticleId IdType="pmc">PMC7167049</ArticleId><ArticleId IdType="pubmed">31967327</ArticleId></ArticleIdList></Reference><Reference><Citation>Schroeder J.T., Bieneman A.P. The S1 subunit of the SARS-CoV-2 spike protein activates human monocytes to produce cytokines linked to COVID-19: Relevance to galectin-3. Front. Immunol. 2022;13:1238. doi: 10.3389/fimmu.2022.831763.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.831763</ArticleId><ArticleId IdType="pmc">PMC8982143</ArticleId><ArticleId IdType="pubmed">35392091</ArticleId></ArticleIdList></Reference><Reference><Citation>Semmarath W., Mapoung S., Umsumarng S., Arjsri P., Srisawad K., Thippraphan P., Yodkeeree S., Dejkriengkraikul P. Cyanidin-3-O-glucoside and peonidin-3-O-glucoside-rich fraction of black rice germ and bran suppresses inflammatory responses from SARS-CoV-2 spike glycoprotein S1-induction in vitro in A549 lung cells and THP-1 macrophages via inhibition of the NLRP3 inflammasome pathway. Nutrients. 2022;14:2738.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9268823</ArticleId><ArticleId IdType="pubmed">35807916</ArticleId></ArticleIdList></Reference><Reference><Citation>Arjsri P., Srisawad K., Mapoung S., Semmarath W., Thippraphan P., Umsumarng S., Yodkeeree S., Dejkriengkraikul P. Hesperetin from Root Extract of Clerodendrum petasites S. Moore Inhibits SARS-CoV-2 Spike Protein S1 Subunit-Induced NLRP3 Inflammasome in A549 Lung Cells via Modulation of the Akt/MAPK/AP-1 Pathway. Int. J. Mol. Sci. 2022;23:10346. doi: 10.3390/ijms231810346.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms231810346</ArticleId><ArticleId IdType="pmc">PMC9498987</ArticleId><ArticleId IdType="pubmed">36142258</ArticleId></ArticleIdList></Reference><Reference><Citation>Dissook S., Umsumarng S., Mapoung S., Semmarath W., Arjsri P., Srisawad K., Dejkriengkraikul P. Luteolin-rich fraction from Perilla frutescens seed meal inhibits spike glycoprotein S1 of SARS-CoV-2-induced NLRP3 inflammasome lung cell inflammation via regulation of JAK1/STAT3 pathway: A potential anti-inflammatory compound against inflammation-induced long-COVID. Front. Med. 2022;9:1072056.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9870545</ArticleId><ArticleId IdType="pubmed">36698809</ArticleId></ArticleIdList></Reference><Reference><Citation>Suresh M.V., Francis S., Aktay S., Kralovich G., Raghavendran K. Therapeutic potential of curcumin in ARDS and COVID-19. Clin. Exp. Pharmacol. Physiol. 2023;50:267&#x2013;276. doi: 10.1111/1440-1681.13744.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1440-1681.13744</ArticleId><ArticleId IdType="pmc">PMC9877870</ArticleId><ArticleId IdType="pubmed">36480131</ArticleId></ArticleIdList></Reference><Reference><Citation>Kushwaha A.D., Mishra K., Singh M., Ganju L., Saraswat D. Nanocurcumin formulation: A possible therapeutic agent for post COVID inflammatory syndrome. Immunopharmacol. Immunotoxicol. 2022;44:141&#x2013;146. doi: 10.1080/08923973.2022.2037631.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08923973.2022.2037631</ArticleId><ArticleId IdType="pubmed">35130792</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehi-Eromosele C. The effect of polyethylene glycol (PEG) coating on the magneto-structural properties and colloidal stability of CO0. 8Mg0. 2Fe2O4 nanoparticles for potential biomedical applications. Dig. J. Nanomater. Biostruct. 2016;11:7&#x2013;14.</Citation></Reference><Reference><Citation>Hasan M., Elkhoury K., Belhaj N., Kahn C., Tamayol A., Barberi-Heyob M., Arab-Tehrany E., Linder M. Growth-inhibitory effect of chitosan-coated liposomes encapsulating curcumin on MCF-7 breast cancer cells. Mar. Drugs. 2020;18:217. doi: 10.3390/md18040217.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/md18040217</ArticleId><ArticleId IdType="pmc">PMC7230998</ArticleId><ArticleId IdType="pubmed">32316578</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao X., Yi X., Liu Z., Dong X., Xia G., Zhang X., Shen X. Comparative study on curcumin loaded in golden pompano (trachinotus blochii) head phospholipid and soybean lecithin liposomes: Preparation, characteristics and anti-inflammatory properties. Molecules. 2021;26:2328. doi: 10.3390/molecules26082328.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules26082328</ArticleId><ArticleId IdType="pmc">PMC8073247</ArticleId><ArticleId IdType="pubmed">33923773</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonaccorso A., Pellitteri R., Ruozi B., Puglia C., Santonocito D., Pignatello R., Musumeci T. Curcumin loaded polymeric vs. lipid nanoparticles: Antioxidant effect on normal and hypoxic olfactory ensheathing cells. Nanomaterials. 2021;11:159. doi: 10.3390/nano11010159.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nano11010159</ArticleId><ArticleId IdType="pmc">PMC7827715</ArticleId><ArticleId IdType="pubmed">33435146</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazumder S., Dewangan A.K., Pavurala N. Enhanced dissolution of poorly soluble antiviral drugs from nanoparticles of cellulose acetate based solid dispersion matrices. Asian J. Pharm. Sci. 2017;12:532&#x2013;541. doi: 10.1016/j.ajps.2017.07.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajps.2017.07.002</ArticleId><ArticleId IdType="pmc">PMC7032198</ArticleId><ArticleId IdType="pubmed">32104366</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;ller R.H., Peters K. Nanosuspensions for the formulation of poorly soluble drugs: I. Preparation by a size-reduction technique. Int. J. Pharm. 1998;160:229&#x2013;237. doi: 10.1016/S0378-5173(97)00311-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0378-5173(97)00311-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia L. Nanoparticle formulation increases oral bioavailability of poorly soluble drugs: Approaches, experimental evidences and theory. Curr. Nanosci. 2005;1:237&#x2013;243. doi: 10.2174/157341305774642939.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/157341305774642939</ArticleId><ArticleId IdType="pmc">PMC2768293</ArticleId><ArticleId IdType="pubmed">19865587</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan S., Shafiei M.S., Longoria C., Schoggins J.W., Savani R.C., Zaki H. SARS-CoV-2 spike protein induces inflammation via TLR2-dependent activation of the NF-&#x3ba;B pathway. eLife. 2021;10:e68563. doi: 10.7554/eLife.68563.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.68563</ArticleId><ArticleId IdType="pmc">PMC8709575</ArticleId><ArticleId IdType="pubmed">34866574</ArticleId></ArticleIdList></Reference><Reference><Citation>Barilli A., Visigalli R., Ferrari F., Bianchi M.G., Dall&#x2019;Asta V., Rotoli B.M. Immune-mediated inflammatory responses of alveolar epithelial cells: Implications for covid-19 lung pathology. Biomedicines. 2022;10:618. doi: 10.3390/biomedicines10030618.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines10030618</ArticleId><ArticleId IdType="pmc">PMC8945544</ArticleId><ArticleId IdType="pubmed">35327420</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelley N., Jeltema D., Duan Y., He Y. The NLRP3 inflammasome: An overview of mechanisms of activation and regulation. Int. J. Mol. Sci. 2019;20:3328. doi: 10.3390/ijms20133328.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20133328</ArticleId><ArticleId IdType="pmc">PMC6651423</ArticleId><ArticleId IdType="pubmed">31284572</ArticleId></ArticleIdList></Reference><Reference><Citation>Jo E.-K., Kim J.K., Shin D.-M., Sasakawa C. Molecular mechanisms regulating NLRP3 inflammasome activation. Cell. Mol. Immunol. 2016;13:148&#x2013;159. doi: 10.1038/cmi.2015.95.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cmi.2015.95</ArticleId><ArticleId IdType="pmc">PMC4786634</ArticleId><ArticleId IdType="pubmed">26549800</ArticleId></ArticleIdList></Reference><Reference><Citation>Dos Santos G., Kutuzov M.A., Ridge K.M. The inflammasome in lung diseases. Am. J. Physiol. Lung Cell Mol. Physiol. 2012;303:627&#x2013;633. doi: 10.1152/ajplung.00225.2012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajplung.00225.2012</ArticleId><ArticleId IdType="pmc">PMC4747913</ArticleId><ArticleId IdType="pubmed">22904168</ArticleId></ArticleIdList></Reference><Reference><Citation>Aboudounya M.M., Heads R.J. COVID-19 and toll-like receptor 4 (TLR4): SARS-CoV-2 may bind and activate TLR4 to increase ACE2 expression, facilitating entry and causing hyperinflammation. Mediat. Inflamm. 2021;2021:8874339. doi: 10.1155/2021/8874339.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2021/8874339</ArticleId><ArticleId IdType="pmc">PMC7811571</ArticleId><ArticleId IdType="pubmed">33505220</ArticleId></ArticleIdList></Reference><Reference><Citation>Sohn K.M., Lee S.-G., Kim H.J., Cheon S., Jeong H., Lee J., Kim I.S., Silwal P., Kim Y.J., Paik S. COVID-19 patients upregulate toll-like receptor 4-mediated inflammatory signaling that mimics bacterial sepsis. J. Korean Med. Sci. 2020;35:e343. doi: 10.3346/jkms.2020.35.e343.</Citation><ArticleIdList><ArticleId IdType="doi">10.3346/jkms.2020.35.e343</ArticleId><ArticleId IdType="pmc">PMC7521960</ArticleId><ArticleId IdType="pubmed">32989935</ArticleId></ArticleIdList></Reference><Reference><Citation>Manik M., Singh R.K. Role of toll-like receptors in modulation of cytokine storm signaling in SARS-CoV-2-induced COVID-19. J. Med. Virol. 2022;94:869&#x2013;877. doi: 10.1002/jmv.27405.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27405</ArticleId><ArticleId IdType="pmc">PMC8662021</ArticleId><ArticleId IdType="pubmed">34672376</ArticleId></ArticleIdList></Reference><Reference><Citation>Hemmat N., Asadzadeh Z., Ahangar N.K., Alemohammad H., Najafzadeh B., Derakhshani A., Baghbanzadeh A., Baghi H.B., Javadrashid D., Najafi S. The roles of signaling pathways in SARS-CoV-2 infection; lessons learned from SARS-CoV and MERS-CoV. Arch. Virol. 2021;166:675&#x2013;696. doi: 10.1007/s00705-021-04958-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00705-021-04958-7</ArticleId><ArticleId IdType="pmc">PMC7812983</ArticleId><ArticleId IdType="pubmed">33462671</ArticleId></ArticleIdList></Reference><Reference><Citation>Boonrueang N., Kiattisin K., Ampasavate C. Effects of Antioxidants and Sun-Screening Agent on the Photostability of Curcumin; Proceedings of the 10th International Conference on Nutrition and Physical Activity in Ageing, Obesity, and Cancer; Chonburi, Thailand. 18&#x2013;20 December 2019; pp. 32&#x2013;42.</Citation></Reference><Reference><Citation>Pradhan N., Parbin S., Kausar C., Kar S., Mawatwal S., Das L., Deb M., Sengupta D., Dhiman R., Patra S.K. Paederia foetida induces anticancer activity by modulating chromatin modification enzymes and altering pro-inflammatory cytokine gene expression in human prostate cancer cells. Food Chem. Toxicol. 2019;130:161&#x2013;173. doi: 10.1016/j.fct.2019.05.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.fct.2019.05.016</ArticleId><ArticleId IdType="pubmed">31112703</ArticleId></ArticleIdList></Reference><Reference><Citation>Plotnikova M.A., Klotchenko S.A., Vasin A.V. Development of a multiplex quantitative PCR assay for the analysis of human cytokine gene expression in influenza A virus-infected cells. J. Immunol. Methods. 2016;430:51&#x2013;55. doi: 10.1016/j.jim.2016.01.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jim.2016.01.005</ArticleId><ArticleId IdType="pubmed">26772136</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Kong H., Zeng X., Liu W., Wang Z., Yan X., Wang H., Xie W. Activation of NLRP3 inflammasome enhances the proliferation and migration of A549 lung cancer cells. Oncol. Rep. 2016;35:2053&#x2013;2064. doi: 10.3892/or.2016.4569.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/or.2016.4569</ArticleId><ArticleId IdType="pubmed">26782741</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>